Open AccessRole of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia
Author(s) -
Swapna Thota,
Aram Oganesian,
Mohammad Azab,
Elizabeth A. Griffiths
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1210
Subject(s) - decitabine , medicine , chronic myelomonocytic leukemia , azacitidine , myelodysplastic syndromes , oncology , international prognostic scoring system , pharmacology , bone marrow , dna methylation , biochemistry , gene expression , chemistry , gene
Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are clonal hematopoietic stem cell disorders. Complex disease biology has posed significant challenge to the development of novel therapeutics. Despite myriad clinical trials, none have been superior to azacitidine and decitabine (DEC) therapy. These therapies present a substantial burden for patients with 5 and 7 days of parenteral treatment in an infusion clinic. To overcome this limitation, a fixed drug combination of oral DEC-cedazuridine (C-DEC), a cytidine deaminase inhibitor with documented safety profile was developed. This drug was recently approved by the US FDA, Australian TGA and Health Canada for newly diagnosed or previously treated intermediate or high risk by international prognostic scoring system, MDS and CMML. In this review, we detail the pharmacokinetic and clinical activity of C-DEC in the management of MDS and CMML.